Missouri legislation · 2026 Regular Session
Missouri HB3059: Creates provisions relating to insurance coverage of prescription drugs for advanced, metastatic cancer
Status: In committee, May 15, 2026
What the bill says
To amend chapter 376, RSMo, by adding thereto one new section relating to insurance coverage of prescription drugs for advanced, metastatic cancer. Section A. Chapter 376, RSMo, is amended by adding thereto one new section, to be known as section 376.2040, to read as follows: 376.2040. 1. As used in this section, the following terms mean: (1) "Advanced, metastatic cancer", cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other areas or parts of the body; (2) "Associated condition", any symptom or side effect that is associated with advan.
From the introduced text:
To amend chapter 376, RSMo, by adding thereto one new section relating to insurance coverage of prescription drugs for advanced, metastatic cancer. Section A. Chapter 376, RSMo, is amended by adding thereto one new section, to be known as section 376.2040, to read as follows: 376.2040. 1. As used in this section, the following terms mean: (1) "Advanced, metastatic cancer", cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other areas or parts of the body; (2) "Associated condition", any symptom or side effect that is associated with advanced, metastatic cancer or its treatment and that, in the judgment of the health care practitioner, further jeopardizes the health of a patient if left untreated; (3) "Enrollee", the same meaning given to the term in section 376.1350; (4) "Health benefit plan", the same meaning given to the term in section 376.1350. The term "health benefit plan" shall also include MO HealthNet. 2. A health benefit plan that provides coverage for advanced, metastatic cancer and associated conditions shall not require, before the health benefit plan provides coverage of a prescription drug for advanced, metastatic cancer or an associated condition, that the or (2) Prove a history of failure of a different drug. 3. This section applies only to a drug the use …